Monash University Study Highlights
A recent investigation by Monash University revealed that taking low doses of aspirin can reduce the likelihood of developing dementia by 70% in older adults who possess a specific platelet-related genetic profile. This finding comes from an in-depth analysis of data collected during the large-scale ASPREE trial, which involved over 13,500 participants. The study’s outcomes were published in Alzheimer's & Dementia: The Journal of Alzheimer's Association.
Key Findings from the ASPREE Trial
Data from the ASPREE trial showed that among individuals within the top 20% of a particular genetic marker, only 1% of aspirin users developed dementia compared to 3.3% in the placebo group. However, aspirin use was linked to a higher risk of major bleeding events—4.4% versus 2.1% in those not taking aspirin—highlighting the need for caution when considering the medication.
Dementia Australia projects a significant rise in dementia cases, estimating an increase from approximately 446,500 individuals in 2026 to over 1 million by 2065. Dr. Peter Franks, commenting on the study, noted that prior research suggested aspirin was ineffective for the general population, but these new insights emphasize the importance of genetic factors in determining who might benefit.
"This advancement could eventually enable healthcare providers to identify patients who will truly benefit from aspirin therapy." Dr. Peter Franks
Before starting aspirin treatment, consulting a healthcare professional is essential to weigh the potential benefits against the risks. While these findings open promising avenues for dementia prevention, further research is necessary to confirm and expand upon these results.
Monash University's discovery holds considerable promise for transforming dementia prevention strategies, particularly among high-risk groups with specific genetic traits. Given the anticipated rise in dementia cases in Australia, these results may help pave the way for more personalized treatment approaches that minimize bleeding risks associated with aspirin use.